Published in Drug Week, December 16th, 2005
These results were presented in a poster session at the International Society for Biological Therapy of Cancer meeting in Alexandria, Virginia. The company's metastatic melanoma clinical program also includes studying talabostat in a phase II trial in combination with cisplatin.
The single-agent trial included 42 patients with metastatic melanoma, 31 of whom are evaluable for response. Two patients had a response to talabostat as defined by Recist (a 30% or greater...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.